Drugs / ET-26HCl
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06764147 | Dec 2023 → Feb 2024 | — | Ahon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06747520 | Nov 2023 → Feb 2024 | impaired renal function disease | Ahon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET-26HCl | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06764147 ↗ |
| Route | Intravenous | “single intravenous injection” NCT06747520 ↗ |